APVO - Aptevo Therapeutics: IXINITY Revenue Still The Focus
As I said in the previous article on the company, my metric for Aptevo Therapeutics (APVO) having a good Q2'19 quarter was even a slight increase in IXINITY revenue (the company's commercial Hemophilia B drug). The company reported IXINITY revenue of $7.4 million, which was up by $0.4M sequentially. As such, I consider the quarter good.
The company lost $13.3M for the quarter or $0.30 per share, beating slightly on revenue but missing adjusted EPS by $0.04. However it's important to note that the company had significant one time costs relating to the